Outcome of Allogeneic Hematopoietic Stem Cell Transplantation

NCT06702111 | Recruiting DMC

• 1 other identifier: ALLO-HSCT-001
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 2

Brief Summary

To collect baseline and outcome data relating to all bone marrow, peripheral blood, cord blood hematopoietic stem cell transplants and therapies related to hematopoietic stem cell transplantation performed in Queen Mary Hospital.

Conditions

Hematopoietic Stem Cell Transplant (HSCT)

Keywords

Hematopoietic stem cell transplantation; Prognostic factors; Outcome

Outcome Measures

Primary Outcomes (2)

• Overall survival

  Time from HSCT to death or latest follow-up

  5 year

• Relapse-free survival

  Time from HSCT to relapse, death or latest follow-up

  5 years

Study Arms (1)

All patients receiving allogeneic HSCT at Queen Mary Hospital, Hong Kong

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients aged 18 years or older who are undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) at Queen Mary Hospital.

You may qualify if:

• Adult patients aged 18 years or older who received allogeneic hematopoietic stem cell transplantation (allo-HSCT).

You may not qualify if:

• participant who is unable to give informed consent in a prospective cohort.

Sponsors & Collaborators

• The University of Hong Kong: lead

Study Sites (2)

Department of Medicine, Queen Mary Hospital

Hong Kong, Hong Kong

RECRUITING

Queen Mary Hospital, Hong Kong

Hong Kong, Hong Kong

RECRUITING

Related Publications (1)

• Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Camara R, Corbacioglu S, Dolstra H, Duarte R, Glass B, Greco R, Lankester AC, Mohty M, Peffault de Latour R, Snowden JA, Yakoub-Agha I, Kroger N; European Society for Blood and Marrow Transplantation (EBMT). Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021 Jul;56(7):1651-1664. doi: 10.1038/s41409-021-01227-8. Epub 2021 Feb 23.

  PMID: 33623153 BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Peripheral blood and bone marrow

Study Officials

• Harry HS Gill, MBBS, MD, FRCP, FRCPath

  Department of Medicine, the University of Hong Kong

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Harry HS Gill, MBBS, MD, FRCP, FRCPath

CONTACT

+852 22555859; gillhsh@hku.hk

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 10 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 20, 2024
• First Posted: November 22, 2024
• Study Start: December 1, 2024
• Primary Completion (Estimated): December 1, 2029
• Study Completion (Estimated): December 1, 2030
• Last Updated: November 27, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share

Locations

HK (2)